News

Latest news

Hide mandatory notifications of trade

Primary insider notification – Allocation overview

(Oslo, Norway, 5 October 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the “Company”) and the announcement on 4 October 2016 regarding the final result of the Rights Offering.

STOCK EXCHANGE ANNOUNCEMENT 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES 

After yesterday’s allocation of shares in the Rights Offering, the primary insiders who were allocated shares in the Rights Offering holds the following interests in the Company: 

Name Position Allocation of shares in the Rights issue Warrants Total number of shares after Rights Issue
Per S. Thoresen through Bekkestua Venture AS Board member 1,183,690 0 1,183,690
Unni Hjelmaas through Hjelmaas AS Acting CEO 473,476 0 473,476
Jens Krøis CFO 195,499 105,600 301,099

Cecilie Grue through Grue Invest AS

Director of legal affairs 195,499 105,600 301,099
Gunnar Flåten Director of Finance 800,000 0 1,617,500
Maja A. Sommerfelt VP, Director of Research & External Innovation 591,106 0 910,393

The subscription price for the shares in the Rights Offering was NOK 0.10 per share. 

Further information

Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jens Krøis, CFO, +45 208 01 668, jk@bionorpharma.com

Link to the announcement in pdf